Icelandirect acquires Soma Labs

Icelandirect LLC, a U.S.-based contract manufacturer for human and pet supplement brands, has acquired Soma Labs, a New Jersey-based supplement manufacturer specializing in solid dosage form production. The transaction closed in February 2026, according to a press release.  The acquisition is an investment in capability ‒ expanding what Icelandirect can build, manufacture, and deliver.

‘For years, we have been known as a leader in lipid and softgel supplement sourcing, formulation, manufacturing and packaging,’ said Brandon Miller, CEO of Icelandirect.  ‘The acquisition of Soma Labs will (…) allow us to take a brand from ingredient and formula all the way through to finished, shelf-ready product ‒ in more formats, at greater scale.’ 

Icelandirect is now able to produce powders with custom blending and filling in flexible packaging formats, hard-shell capsules supporting a wide range of fill types including powders, beadlets, and oils, compressed tablets as well as chewables.

According to company information, Soma Labs will now operate as an integrated division of Icelandirect, with its New Jersey facility remaining fully operational. Leadership and technical teams will be integrated into the broader Icelandirect organization to ensure seamless alignment across quality systems, supply chain operations, and customer service functions.